Stock comparison
Arbutus Biopharma
IDEXX Laboratories
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
ABUS
Arbutus Biopharma
Market cap
$859.29M
Sector
Healthcare
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | ABUS | IDXX | Winner |
|---|---|---|---|
| Warren Buffett | 49D | 75B | IDXX |
| Benjamin Graham | 43D | 80A | IDXX |
| Philip Fisher | 55C | 75B | IDXX |
| Peter Lynch | 48D | 71B | IDXX |
| Joel Greenblatt | 100A | 83C | ABUS |
| Charlie Munger | 64D | 87A | IDXX |
| Terry Smith | 66B | 84A | IDXX |
Side-by-side metrics
| Metric | ABUS | IDXX |
|---|---|---|
| Market cap | $859.29M | $44.12B |
| P/E (TTM) | 5.1x | 39.0x |
| EV/EBIT | - | 31.6x |
| ROIC (TTM) | 56.72% | 40.66% |
| Gross margin | 99.98% | 62.05% |
| Net margin | 83.95% | 24.63% |
| Revenue CAGR 5y | 6.4% | 7.56% |
| EPS CAGR 5y | - | 10.79% |
| Debt / Equity | 0.0x | 0.7x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
ABUS leads on
- EV/EBIT-vs 31.6x+194%
- Debt / Equity0.0xvs 0.7x+100%
- P/E (TTM)5.1xvs 39.0x+87%
- Net margin83.95%vs 24.63%+71%
IDXX leads on
- Market cap$44.12Bvs $859.29M+98%
- Revenue CAGR 5y7.56%vs 6.4%+15%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.